

1 **Title:** Comparative Effectiveness of BNT162b2 and NVX-CoV2373 Vaccines in Korean Adults

2 **Authors:** Seon Kyeong Park^{1*}, Young June Choe^{2*}, Seung Ah Choe³, Benjamin John Cowling⁴,

3 Ji Hae Hwang¹, Ju Hee Lee¹, Kil Hun Lee¹, Seonju Yi¹, Sang Won Lee¹, Geun-Yong Kwon¹, Eun

4 Jung Jang¹, Ryu Kyung Kim¹, Young-Joon Park¹

5 *Equally contributed to the manuscript

6 **Affiliations:** ¹Director for Epidemiological Investigation Analysis, Korea Disease Control and

7 Prevention Agency, Cheongju, Korea; ²Department of Pediatrics, Korea University Anam

8 Hospital, and Allergy and Immunology Center, Korea University, Seoul, Korea; ³Department of

9 Preventive Medicine, Korea University College of Medicine, Seoul, Korea; ⁴WHO Collaborating

10 Centre for Infectious Disease Epidemiology and Control, School of Public Health, The

11 University of Hong Kong, Pokfulam, Hong Kong

12 **Correspondence:** Young-Joon Park, MD, MPH. Director for Epidemiological Investigation

13 Analysis, Korea Disease Control and Prevention Agency, Osong Health Technology

14 Administration Complex, 187 Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju

15 28159, Korea. Email: pahmun@korea.kr

16 **Key points:** COVID-19; Korea; SARS-CoV-2; vaccine effectiveness; BNT162b2; NVX-

17 CoV2373

18

19

20

21 **Abstract**

22 **Background:** Various types of vaccines against SARS-CoV-2 have reduced the burden of
23 coronavirus diseases 2019 (COVID-19) across the world. We conducted an observational study
24 to evaluate the effectiveness of NVX-CoV2373 and BNT162b2 in providing protection in
25 Korean adults.

26 **Methods:** This study was a retrospective matched cohort study to emulate a target trial of three
27 doses of NVX-CoV2373 (N-N-N) versus three doses of BNT162b2 (B-B-B) vaccines in
28 presumed immune-naive adults. We used data from the Korea COVID-19 Vaccine Effectiveness
29 (K-COVE) cohort, combining all COVID-19 laboratory-confirmed cases and all COVID-19
30 immunization registry, between February and November 2022. We calculated 40-week risk
31 differences and risk ratios between the two vaccines.

32 **Results:** A total of 3,019 recipients of NVX-CoV2373 vaccine and 3,027 recipients of
33 BNT162b2 vaccine were eligible for the study. The 40-week risk ratios for recipients of the
34 NVX-CoV2373 vaccine as compared with recipients of the BNT162b2 vaccine were 1.169 (95%
35 CI, 1.015 to 1.347) for laboratory-confirmed SARS-CoV-2 infection, and 0.504 (95% CI, 0.126
36 to 2.014) for severe SARS-CoV-2 infection. Estimated risk of severe infection was 0.001 events
37 per 1000 persons (95% CI, 0 to 0.003) for the NVX-CoV2373 vaccine and 0.002 events per 1000
38 persons (95% CI, 0.001 to 0.006) for BNT162b2 vaccine.

39 **Conclusion:** This study identifies reduced risk of SARS-CoV-2 infection and severe infection
40 after receipt of three doses of either NVX-CoV2373 or BNT162b2 vaccines in Korean adults.

41 Direct, vaccine-conferred protection may be of importance among high risk persons to mitigate
42 from serious clinical outcome from COVID-19.

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59 **Introduction**

60 Various types of vaccines against SARS-CoV-2 have reduced the burden of coronavirus
61 diseases 2019 (COVID-19) across the world [1]. However, global problem with supply and
62 ongoing demand for booster doses of COVID-19 vaccines makes large portion of population
63 under-immunized [2]. Moreover, allergic reaction to certain types of vaccines calls upon the
64 medical needs for other options to prevent from severe COVID-19 [3, 4].

65 The recombinant protein-based vaccine NVX-CoV2373 has demonstrated high
66 immunogenicity and efficacy against COVID-19 and has been introduced in more than 40
67 countries [5, 6]. Despite its use in different settings, the comparative effectiveness of NVX-
68 CoV2373 and other COVID-19 vaccines for the prevention of SARS-CoV-2 infection has yet to
69 be assessed.

70 Since the beginning of COVID-19 pandemic, South Korean government has been
71 operating a centralized public health database that collects all reported COVID-19 cases and
72 their vaccination status [7]. The NVX-CoV2373 vaccine was introduced in South Korea on
73 March 2022, and as of February 2023, more than 300,000 doses have been distributed [8]. With
74 real-time vaccine registry merged with COVID-19 surveillance data, there is an opportunity to
75 assess the comparative effectiveness of NVX-CoV2373 vaccine [9, 10].

76 Herein, we conducted an observational study in which we evaluated the effectiveness of
77 NVX-CoV2373 and BNT162b2 in providing protection against SARS-CoV-2 infection and
78 severe infection in Korean adults.

79

80 **Methods**

81 This study was a retrospective matched cohort study to emulate a target trial of three
82 doses of NVX-CoV2373 (N-N-N) versus three doses of BNT162b2 (B-B-B) vaccines in
83 presumed immune-naive adults. We used data from the Korea COVID-19 Vaccine Effectiveness
84 (K-COVE) cohort, a large-linked database combining all COVID-19 laboratory-confirmed cases
85 and all COVID-19 immunization registry in South Korea. Detailed information about the K-
86 COVE cohort has been published previously [11-13].

87 In current study, 4,547,432 Korean adults ≥ 18 yrs. of age without a previously
88 documented SARS-CoV-2 infection or COVID-19 vaccination, as of February 14, 2022, were
89 initially screened. Eligibility criteria included all Korean nationals aged at least 18 years, no
90 previously documented SARS-CoV-2 infection, and has had three doses of NVX-CoV2373 or
91 BNT162b2 vaccines between February 14 and November 26, 2022 (286 days). Matching criteria
92 included age, sex, geographic region, and health status (immunocompromised vs. not). The
93 detailed case selection flow is shown in Figure 1.

94 The interventions of interest were the third-dose vaccination with NVX-CoV2373
95 vaccine (after receipt of two doses of NVX-CoV2373) or the third-dose of BNT162b2 vaccine
96 (after receipt of two doses of BNT162b2). Between February and November 2022, there was no
97 preferential recommendation issued by the government or academic society between NVX-
98 CoV2373 or BNT162b2 vaccines, and all persons aged 12 years and above were eligible for free
99 vaccination during this period. Per national guideline, both NVX-CoV2373 BNT162b2 vaccine's
100 schedules were as follows: two doses in interval of 3 weeks; followed by a third dose booster
101 after 3 months, and a fourth dose booster after 4 months. The third dose booster vaccination was

102 recommended for all adults aged 18 years and above; while the fourth dose booster vaccination
103 was first recommended to immunocompromised patients (18-49 years) and adults aged 50 years
104 and above, but was opened to all adults who were willing to get vaccinated. Per national
105 guideline, booster series with homologous vaccine type was recommended (i.e., N-N-N or B-B-
106 B).

107 The two outcomes of interest were (1) laboratory-confirmed SARS-CoV-2 infection, and
108 (2) severe SARS-CoV-2 infection. Laboratory-confirmed SARS-CoV-2 infection include either
109 rapid antigen test (RAT) and polymerase chain reaction (PCR) test, conducted by healthcare
110 professionals. Severe SARS-CoV-2 infection is defined if the patient was treated with high flow
111 oxygen, invasive mechanical ventilation, extracorporeal membrane oxygenation, continuous
112 renal replacement therapy, or death attributable to COVID-19, within 30 days following
113 diagnosis of COVID-19.

114 For each eligible participant, follow-up started on the day the first dose of vaccine was
115 received and ended on the day of the outcome of interest or the end of the study, whichever
116 occurred first. Observed period was from February 14, 2022, to November 26, 2022 for SARS-
117 CoV-2 infection; and for severe infection, the observed period was extended through December
118 24, 2022. Supplemental Figure 1 shows the trend of national virus genomic surveillance data
119 suggesting that BA.2, BA.2.3., and BA.5 were the main circulating subvariant during the
120 observed period.

121 We used the Kaplan–Meier estimator with daily outcome events to compute the risk of
122 the outcome during the period, then calculated 40-week risk differences and risk ratios between

123 the NVX-CoV2373 and BNT162b2 groups. Statistical analyses were conducted using R v.4.02
124 (R Core Team, Vienna, Austria).

125 This study was conducted as a legally mandated public health investigation under the
126 authority of the Korean Infectious Diseases Control and Prevention Act. The study was approved
127 by the Korea Disease Control and Prevention Agency Institutional Review Board (IRB No.
128 2021-12-03-PE-A).

129

130 **Results**

131 Among the 14,325 Korean adults who received their third dose of NVX-CoV2373 or
132 BNT162b2 vaccines after February 14, 2022, a total of 3,019 recipients of NVX-CoV2373
133 vaccine and 3,027 recipients of BNT162b2 vaccine were eligible for the study (Figure 1). The
134 baseline characteristics of matched persons is shown in Table 1. The median age was 54 years in
135 both groups, female-to-male ratio was 55:45, and 0.1%-0.2% were long-term care facility
136 residents, and 7.4%-7.5% were immunocompromised patients. The median follow-up period was
137 97.19 days for NVX-CoV2373 recipients and 97.61 days for BNT162b2 recipients.
138 Supplementary Table 1 shows the characteristics of unmatched NVX-CoV2373 recipients, and
139 Supplementary Table 2 shows the characteristics of unvaccinated, 1-dose vaccinated, 2-dose
140 vaccinated, and those who received heterologous booster 3-doses.

141 Over a 40-week follow-up period, there were 769 SARS-CoV-2 laboratory-confirmed
142 infection and of those, nine cases (1.1 %) were classified as severe infection (Table 2). Of the
143 413 laboratory-confirmed-infection among NVX-CoV2373 recipients, three cases (0.7%) were

144 classified as severe infection; while of the 356 laboratory-confirmed-infection among BNT162b2
145 recipients, six (1.7%) were classified as severe infection. The 40-week risk ratios for recipients
146 of the NVX-CoV2373 vaccine as compared with recipients of the BNT162b2 vaccine were 1.169
147 (95% CI, 1.015 to 1.347) for laboratory-confirmed SARS-CoV-2 infection, and 0.504 (95% CI,
148 0.126 to 2.014) for severe SARS-CoV-2 infection (Table 2). The risk differences (BNT162b2
149 minus NVX-CoV2373), expressed as events over 40 weeks per 1,000 persons, were 1.214 (95%
150 CI, 1.083 to 1.337) for laboratory-confirmed SARS-CoV-2 infection, and 0.020 (95% CI, 0.007
151 to 0.044) for severe infection. Supplementary Table 3 shows age-specific risk ratio and risk
152 difference.

153 Figure 1 shows the cumulative incidence curves for the study outcomes in each vaccine
154 groups. The absolute risks of the outcomes were low in both groups, with estimated risk of all
155 laboratory-confirmed infection was 0.162 events per 1000 persons (95% CI, 0.147 to 0.178) for
156 the NVX-CoV2373 vaccine and 0.140 events per 1000 persons (95% CI, 0.126 to 0.155) for
157 BNT162b2 vaccine. Estimated risk of severe infection was 0.001 events per 1000 persons (95%
158 CI, 0 to 0.003) for the NVX-CoV2373 vaccine and 0.002 events per 1000 persons (95% CI,
159 0.001 to 0.006) for BNT162b2 vaccine.

160

161 **Discussion**

162 The target trial emulation study we performed in the South Korea demonstrated that the
163 three-dose BNT162b2 had lower risk of all laboratory-confirmed infection compared to NVX-
164 CoV2373, however, the risk of severe infection was similarly low in both vaccines. Our finding

165 provides strong support for the current indication and recommendation that NVX-CoV2373
166 provide robust effectiveness against COVID-19 and its serious outcome. Also, the result is in line
167 with previous meta-analysis that pooled 57 studies that showed vaccine effectiveness of 77.1%-
168 98.0% and 86.3%-93.6% for BNT162b2 and NVX-CoV2373 vaccines against SARS-CoV-2
169 infection, respectively [14]. An Australian study that compared rates of SARS-CoV-2 Omicron
170 BA.1/2 infection showed an adjusted hazard ratio for SARS-CoV-2 infection of NVX-CoV2373
171 recipients compared to BNT162b2 vaccine was 1.70 (1.46-1.97) [15]. These findings may be
172 related to NVX-CoV2373 vaccine's less inducing of spike-specific CD8 T cells compared to
173 mRNA vaccines, as demonstrated in a German immunogenicity study [16].

174 Despite the difference in protection against all SARS-CoV-2 infection between the two
175 vaccines, our finding suggests a comparable protective effect against severe infection in both
176 NVX-CoV2373 and BNT162b2 vaccines. A recent randomized trial from the U.S. and Mexico
177 showed the vaccine efficacy of NVX-CoV2373 against moderate-to-severe COVID-19 of 100%,
178 which is in line with our finding [17]. Other immunologic data supports the result we present. A
179 comparative immunogenicity study with BNT162b2 or mRNA-1273 showed that the NVX-
180 CoV2373 have strongly induced spike-specific antibodies and the CD4 T-cells equally
181 recognized all tested variants from Alpha to Omicron [16], which is further supported by a data
182 showing NVX-CoV2373 inducing high functional T-cell immunity [18]. Together with the real-
183 world data that we present, these findings suggest a robust evidence that NVX-CoV2373
184 provides enhanced protection against severe disease caused by SARS-CoV-2.

185 The observed period was predominated by the Omicron BA.1, BA.2, and BA.4/5
186 variants, therefore, our finding suggests a net benefit from the predecessor vaccine with original

187 strain in mitigating from serious health outcome from SARS-CoV-2 variant [19, 20]. A study
188 evaluating immunogenicity of fourth homologous dose of NVX-CoV2373 showed an
189 enhanced cross-reactive immunity to SARS-CoV-2 variants, suggesting broader protection
190 against emerging SARS-CoV-2 variants [21]. These findings suggest that under current level of
191 circulation of Omicron BA.5 subvariant and in the context of primary immunization with
192 monovalent COVID-19 vaccines, receipt of booster doses may substantially reduce the disease
193 burden in adult population. The homologous booster dose of NVX-CoV2373 vaccine in a phase
194 2 trial suggested a robust immunogenicity of IgG geometric mean titers (GMT) increased of
195 more than 4-folds against ancestral SARS-CoV-2 strain [22]. In the current study, we only
196 included those who were vaccinated with all three doses of NVX-CoV2373, however, a further
197 study is needed to assess the effectiveness of heterologous vaccination with other types of
198 vaccines. One study that measured heterologous NVX-CoV2373 booster vaccination showed
199 enhanced cross-reactive immunity against Omicron BA.1/BA.5 subvariants [23].

200 .This study has limitations. First, our finding does not account for potential changes over
201 time in indirect protection as a result of change in population immunity from natural infection
202 but this should not have a differential effect on recipients of NVX-CoV2373 or BNT162b2.
203 Second, we were unable to examine comorbidities and other unmeasured socioeconomic factors
204 and their impact on choice of vaccination or risk of infection, and our results might therefore
205 suffer from confounding. Lastly, SARS-CoV-2 genotypes in individual breakthrough cases were
206 unknown, which may limit the interpretation of our results. Despite these limitations, a key
207 strength of this study is that it showed NVX-CoV2373 vaccine's effectiveness in a large scale of
208 population, including population with an increased risk of COVID-19. Long-term follow-up ins

209 planned to compare the results in NVX-CoV2373 recipients with those who received other
210 vaccines.

211 In conclusion, our study identifies reduced risk of SARS-CoV-2 infection and severe
212 infection after receipt of three doses of either NVX-CoV2373 or BNT162b2 vaccines in Korean
213 adults. Direct, vaccine-conferred protection may be of importance among high risk persons to
214 mitigate from serious clinical outcome from COVID-19. Updated assessments of the vaccine
215 effectiveness of other COVID-19 vaccines are warranted in light of real-world evidence of
216 vaccine direct effects against evolving variants of SARS-CoV-2.

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231 **Acknowledgement:** We thank the K-COVE data team for their roles in developing and
232 managing the datasets. We also thank Dr. Mark Thompson and Dr. Muruga Vadivale (both from
233 Novavax Inc.) for advice and feedback in developing this study. Data is not publicly available.

234 **Author contribution:** Conceived and designed the analyses: S.K.P., Y.J.C., Y.J.P., Performed
235 data extraction and analyzed data: S.K.P., H.H., J.H.L., K.H.L., Data curation and project
236 management: S.Y., G.Y.K., E.J.J., R.K.K., Contributed to analysis: Y.J.C., S.A.C., B.J.C., Y.J.P.,
237 Wrote the paper: S.K.P., Y.J.C., Y.J.P.

238 **Funding:** None

239

240

241

242

243

244

245

246

247

248

249

250 **Figure legends**

251 Figure 1. Selection of Persons for the Emulation of a Target Trial Evaluating the Comparative
252 Effectiveness of the NVX-CoV2373 and BNT162b2 Vaccines during a Period Marked by SARS-
253 CoV-2 Omicron-Variant Predominance (February - November, 2022).

254 Figure 2. Cumulative Incidence of COVID-19 Outcomes during a Period Marked by SARS-
255 CoV-2 Omicron-Variant Predominance (February- November, 2022).

256 Supplementary Figure 1. SARS-CoV-2 subvariants by surveillance week

257

258

259

260

261

262

263

264

265

266

267

268 **References**

- 269 1. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the
270 first year of COVID-19 vaccination: a mathematical modelling study. *The Lancet*
271 *Infectious diseases* **2022**; 22(9): 1293-302.
- 272 2. The Lancet Infectious D. COVID-19 vaccine equity and booster doses. *The Lancet*
273 *Infectious diseases* **2021**; 21(9): 1193.
- 274 3. Blumenthal KG, Robinson LB, Camargo CA, Jr., et al. Acute Allergic Reactions to
275 mRNA COVID-19 Vaccines. *Jama* **2021**; 325(15): 1562-5.
- 276 4. Greenhawt M, Abrams EM, Shaker M, et al. The Risk of Allergic Reaction to SARS-
277 CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review,
278 Meta-Analysis, GRADE Assessment, and International Consensus Approach. *J Allergy*
279 *Clin Immunol Pract* **2021**; 9(10): 3546-67.
- 280 5. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19
281 Vaccine. *The New England journal of medicine* **2021**; 385(13): 1172-83.
- 282 6. Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike
283 Protein Nanoparticle Vaccine. *The New England journal of medicine* **2020**; 383(24):
284 2320-32.

- 285 7. Yoo KJ, Kwon S, Choi Y, Bishai DM. Systematic assessment of South Korea's
286 capabilities to control COVID-19. *Health Policy* **2021**; 125(5): 568-76.
- 287 8. Central Disease Control headquarters. COVID-19 Vaccination. Accessed at
288 <https://nev.kdca.go.kr/eng/>; Accessed on: February 14, 2023.
- 289 9. Kwon SL, Oh J. COVID-19 vaccination program in South Korea: A long journey toward
290 a new normal. *Health policy and technology* **2022**; 11(2): 100601.
- 291 10. Yi S, Choe YJ, Lim DS, et al. Impact of national Covid-19 vaccination Campaign, South
292 Korea. *Vaccine* **2022**; 40(26): 3670-5.
- 293 11. Jang EJ, Choe YJ, Kim RK, Park YJ. BNT162b2 Vaccine Effectiveness Against the
294 SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years. *JAMA pediatrics* **2023**.
- 295 12. Kim J, Choe YJ, Jang EJ, et al. Effectiveness of Booster mRNA Vaccines Against SARS-
296 CoV-2 Infection in an Elderly Population, South Korea, October 2021-January 2022.
297 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of*
298 *America* **2022**; 75(5): 920-1.
- 299 13. Kim YY, Choe YJ, Kim J, et al. Effectiveness of Second mRNA COVID-19 Booster
300 Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents.
301 *Emerging infectious diseases* **2022**; 28(11): 2165-70.
- 302 14. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against
303 SARS-CoV-2 variants of concern: a systematic review and meta-analysis. *BMC medicine*
304 **2022**; 20(1): 200.
- 305 15. Liu B, Stepien S, Qian J, et al. Comparative effectiveness of four COVID-19 vaccines,
306 BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against
307 SARS-CoV-2 B.1.1.529 (Omicron) infection. *medRxiv* **2022**: 2022.12.22.22283869.

- 308 16. Hielscher F, Schmidt T, Klemis V, et al. NVX-CoV2373-induced cellular and humoral
309 immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and
310 mRNA-1273-regimens. *Journal of clinical virology : the official publication of the Pan
311 American Society for Clinical Virology* **2022**; 157: 105321.
- 312 17. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults
313 in the United States and Mexico. *The New England journal of medicine* **2022**; 386(6):
314 531-43.
- 315 18. Rydyznski Moderbacher C, Kim C, Mateus J, et al. NVX-CoV2373 vaccination induces
316 functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. *The Journal of
317 clinical investigation* **2022**; 132(19).
- 318 19. Bhiman JN, Richardson SI, Lambson BE, et al. Novavax NVX-COV2373 triggers
319 neutralization of Omicron sub-lineages. *Scientific reports* **2023**; 13(1): 1222.
- 320 20. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine
321 against the B.1.351 Variant. *The New England journal of medicine* **2021**; 384(20): 1899-
322 909.
- 323 21. Alves K, Plested JS, Galbiati S, et al. Immunogenicity of a Fourth Homologous Dose of
324 NVX-CoV2373. *The New England journal of medicine* **2023**.
- 325 22. Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a
326 homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-
327 CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. *The
328 Lancet Infectious diseases* **2022**; 22(11): 1565-76.

- 329 23. Choi MJ, Choi JY, Hyun H, et al. Cross-neutralization of Omicron subvariants after
330 heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected
331 and infection-naive individuals. *The Journal of infection* **2023**; 86(2): e46-e8.

332

Study Period : 22.2.14~22.11.26
(severe or death follow up until 22.12.24)

45,447,432 Korean adults ≥ 18 yr of age
without a previously documented
SARS-CoV-2 infection or COVID-19
vaccination, as of February 14, 2022

42,463,357 Were excluded
42,069,593 Were vaccinated before **February 14, 2022**
383,930 Non-Korean citizens
222 Vaccination error
2,068 Confirm abroad
3 Vaccinated abroad
476 Had an incomplete Covid-19 vaccination record
3,794 Had Janssen or SKY Covid-19 vaccination record
3,271 Had a 4th or winter season Covid-19 vaccination record

2,984,075 Were vaccinated after **February 14, 2022**, or Unvaccinated
(All 3 doses of the vaccine recipient were vaccinated after 60 days of the
2nd dose)

2,969,750 Were excluded
2,824,268 Were unvaccinated between February 14 and November 26, 2022
53,385 Received 1 dose of the NVX-CoV2373 or BNT 162b2 Vaccine
91,643 Received 2 doses of the NVX-CoV2373 or BNT 162b2 Vaccine
454 Received 3 doses of the heterologous NVX-CoV2373 or BNT 162b2 Vaccine

14,325 Were evaluated for inclusion in the
study(Received 3doses of the NVX-CoV2373
or BNT 162b2 Vaccine)


11,298 Received 3doses of the NVX-
CoV2373 Vaccine

3,027 Received 3doses of the
BNT162b2 Vaccine


**1:1 matching based on the sex, age group, geographic
region, and health status (immunocompromised vs. not)**

3,019 Were included in the matched
cohort

3,027 Were included in the matched
cohort



2-A) All laboratory-confirmed infection



2-B) Severe infection

